Table 1. PICOS criteria for the ABI economic review.

Criteria	Inclusion	Exclusion
Population	The population of interest will be individuals over 18 years old who have a mild, moderate, and/or severe type of acquired brain injury The term acquired brain injury (ABI): describes any injury sustained to the brain since birth. The Royal College of Physicians 30 have defined ABI as an inclusive category of injuries that embraces acute (rapid onset) brain injury of any cause, including:     -  trauma due to having a head injury (traumatic brain injury, TBI), or     -  vascular accident (sub-arachnoid haemorrhage or stroke),     -  metabolic or toxic insult (e.g. hypoglycaemia)     -  post-surgical damage (e.g. following a brain tumour removal),     -  cerebral anoxia,     -  other inflammation (e.g. vasculitis), or     -  infection (e.g. encephalitis, meningitis) Commonly, brain injuries can be sustained traumatically (TBI) following:     -  motor vehicle or road traffic accidents,     -  falls, or     -  assaults, or, according to 31 can be the result of a non-traumatic cause, such as :     -  stroke,     -  brain illness or tumor,     -  among other conditions There will be no restrictions on ABI participant characteristics such as age, gender, severity of acquired brain injury, study setting or country.	Interventions involving only children aged under 18 years of age will be excluded, due to the brain not being fully mature before this age, therefore being unable to rule out natural development versus recovery. Populations with mild cognitive impairment or other neurological disorders not related to ABI (i.e. dementia), will be excluded.
Interventions	Non-pharmacological rehabilitation intervention for people with an ABI (e.g., any treatment not involving drugs)	Pharmacological interventions that involve the consumption of a substance (including drugs, food supplements, herbal medicines, vitamins and homeopathic remedies.
Comparators	Usual care (UC) or treatment as usual (TAU).	Interventions that did not state a comparator intervention.
Outcomes	Patients: -Cost outcomes: Costs from healthcare and/or societal perspective; intervention costs; productivity loss costs due morbidity and mortality -Health outcomes: Health related quality of life (HQOL) measured as quality adjusted life years (QALY) by any instrument (e.g.: SF-6D or EQ-5D) or quality of life (QOL) measured by any instrument and disease specific health outcomes such as: days of institutionalized delayed, time to care home admission, hospital admission, etc. Care givers: -Cost outcomes: Heath-related cost or, productivity loss due to caregiving -Health outcomes: HQOL or QOL or psychosocial measures of caregiver burden etc. Results: -Net monetary benefit (NMB) -Incremental cost-effectiveness ratio (ICER) -Net health benefit (NHB)	Other than listed under inclusion criteria.
Study designs	Cost-effectiveness analysis (e.g., cost per life year gained), cost-benefit and cost minimization analyses in which the designs were randomised controlled trials (RCTs), non-RCT studies, cost-utility analyses (e.g., cost per quality-adjusted life year (QALY) gained or cost per disability-adjusted life year averted), cohort studies, and modeling studies.	Cost of illness studies (Col), editorials or other descriptive studies (e.g., protocols, single case reports) will be excluded.
General	Studies conducted anywhere in the world will be included, but only English language sources will be consulted. No date restrictions will be applied: sources will be searched from inception up to 24 th August 2020.	Non-English language studies